Product Description
Mechanisms of Action: Sirt1 Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sirtris
Company Location: CAMBRIDGE MA 02139
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes|Psoriasis
Phase 1: Muscular Atrophy|Sepsis|Psoriasis|Chronic Obstructive Pulmonary Disease|Type 2 Diabetes|Colitis, Ulcerative
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT01453491 | P1 |
Completed |
Colitis, Ulcerative |
2013-03-18 |
2019-03-19 |
Treatments |
|
| NCT01702493 | P1 |
Completed |
Psoriasis |
2012-12-05 |
2019-03-19 |
||
| NCT01031108 | P1 |
Completed |
Type 2 Diabetes |
2011-10-12 |
2019-03-19 |
Treatments |
|
| SRT-2104-003 | P1 |
Withdrawn |
Muscular Atrophy |
2011-02-01 |
2019-03-19 |
Treatments |
|
| NCT01014117 | P1 |
Completed |
Sepsis |
2010-05-10 |
2019-03-19 |
Treatments |
|
| NCT00964340 | P1 |
Completed |
Muscular Atrophy |
2010-04-27 |
2019-03-18 |
Treatments |
|
| NCT00920660 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2009-06-12 |
2019-03-18 |
Treatments |
|
| NCT00933062 | P1 |
Completed |
Type 2 Diabetes |
2009-05-12 |
2019-03-18 |
Treatments |
|
| NCT00938275 | P1 |
Completed |
Type 2 Diabetes |
2009-03-27 |
2019-03-18 |
Treatments |
|
| NCT00937872 | P1 |
Completed |
Type 2 Diabetes |
2008-12-22 |
2019-03-18 |
Treatments |
|
| NCT00933530 | P1 |
Completed |
Type 2 Diabetes |
2008-11-01 |
2019-03-18 |
Treatments |
|
| NCT01154101 | P2 |
Completed |
Psoriasis |
2011-11-09 |
2019-03-19 |
Treatments |
|
| NCT01018017 | P2 |
Completed |
Type 2 Diabetes |
2010-12-25 |
2019-03-19 |
Treatments |
|
| 2009-016537-98 | P2 |
Completed |
Type 2 Diabetes |
2010-12-22 |
2022-03-13 |
Treatments |
|
| NCT00937326 | P2 |
Completed |
Type 2 Diabetes |
2010-09-18 |
2019-03-18 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/01/2024 |
PubMed |
SIRT1/SREBPs-mediated regulation of lipid metabolism. |
|
05/13/2024 |
PubMed |
Sirt1 inhibits macrophage polarization and inflammation in gouty arthritis by inhibiting the MAPK/NF-κB/AP-1 pathway and activating the Nrf2/HO-1 pathway. |
|
03/06/2024 |
PubMed |
Emerging roles of SIRT1 activator, SRT2104, in disease treatment. |